Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis

Besien, Jeroen Van; Keller, Etienne Xavier; Somani, Bhaskar; Pietropaolo, Amelia; Claessens, Marc; Merckx, L.; Tailly, Thomas; Coninck, Vincent De

doi:10.1016/j.euf.2021.10.002

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Van Besien et al (2022) conducted a meta-analysis of mirabegron versus a placebo-controlled group in treating SRSs. Although only two RCTs were pooled for meta-analysis, the results showed a significant difference in favor of mirabegron in reducing USSQ urinary symptoms ( p < 0.0001), IPSS ( p = 0.006), and QoL ( p = 0.0006).…”

Section: Discussionmentioning

confidence: 99%

“…Mirabegron, a β3 adrenergic receptor agonist, is recommended as an alternative treatment for SRSs with muscarine antagonist monotherapy ( Sacomani et al, 2019 ). It significantly benefits the treatment of ureteral SRSs when compared to placebo or blank control ( Li et al, 2022 ; Van Besien et al, 2022 ). A recent study has suggested that mirabegron has a favorable balance of efficacy and tolerability ( Kelleher et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Lu,

Li,

Zou

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: We conducted a meta-analysis to assess the efficacy and safety of mirabegron (50 mg/day) and antimuscarinics in treating ureteral stent-related symptoms (SRSs).Methods: All randomized controlled trials (RCTs) were identified by searching PubMed, Embase, Web of Science, and Cochrane Library. The RevMan version 5.3.0 software was used for statistical analysis.Results: This meta-analysis included five RCTs involving 317 patients. A fixed effects model revealed that mirabegron was superior to antimuscarinics in treating urinary symptoms (MD −1.39, 95% CI −2.63 to −0.15, p = 0.03) and general health (MD −1.65, 95% CI −2.60 to −0.69, p = 0.0007) 1 week after treatment initiation. We observed no significant differences in body pain (MD 0.05, 95% CI −1.06 to 1.15, p = 0.94), work performance (MD −0.86, 95% CI −1.77 to 0.06, p = 0.07), and sexual matters (MD 0.03, 95% CI −0.77 to 0.83, p = 0.94). Two weeks after treatment initiation, the ureteral stent symptom questionnaire (USSQ) revealed no significant differences between the two groups. The mirabegron group demonstrated a significant improvement in the quality of life (QoL) (MD −0.18, 95% CI −0.34 to −0.01, p = 0.03), while the International Prostate Symptom Score did not reveal a significant difference between the two groups (MD −0.74, 95% CI −1.79 to 0.32, p = 0.17). Regarding safety, a pooled data analysis presented that the incidence of constipation was lower in the mirabegron group (OR 0.10, 95% CI 0.01 to 0.77, p = 0.03). The mirabegron and antimuscarinics groups did not differ significantly concerning the risk of dry mouth (OR 0.15, 95% CI 0.02 to 1.27, p = 0.08).Conclusion: Mirabegron is superior to antimuscarinics in alleviating ureteral SRSs and improving QoL. Additionally, mirabegron 50 mg/day presented safety with a lower incidence of constipation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Lu,

Li,

Zou

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Impact of Ureteral Stent Material on Stent-related Symptoms: A Systematic Review of the Literature

Boeykens¹,

Keller²,

Bosio³

et al. 2022

European Urology Open Science

View full text Add to dashboard Cite

Ureteroscopic treatment of urolithiasis: How do we measure and optimise outcomes?

Smith,

Rossi,

Smith

et al. 2024

Journal of Clinical Urology

View full text Add to dashboard Cite

Background: Patients with urolithiasis have access to a wide range of efficacious therapeutic surgical options, including shockwave lithotripsy (SWL), retrograde ureteric or intrarenal surgery with semi-rigid and flexible ureteroscopes (URS or fURS) and percutaneous nephrolithotomy (PCNL). In recent years, there have been many peer-reviewed publications evaluating new techniques and new equipment, such as pulse-modulated Holmium:YAG and thulium fibre lasers. However, when reviewing this extensive literature, it becomes apparent that there is no consensus on what constitutes a ‘successful’ stone treatment outcome. Objectives: The purpose of this article is to review the existing measures of ‘success’ after the ureteroscopic treatment of urolithiasis and to promote a standardised and holistic approach to reporting outcomes in clinical trials. Methods: Our narrative review focussed on studies examining measures of success in urolithiasis treatment published within the last 10 years. Conclusions: Due to markedly different reported outcome measures of treatments for urolithiasis, comparing results between studies can be difficult. In addition to measuring clinical outcomes, there is an increasing acknowledgement of the importance of patient-reported outcome measures (PROMs) in determining treatment success, and the need to consider the cost-effectiveness and environmental sustainability of various treatments. We suggest that all future studies on this common urological condition should incorporate holistic and tranpsarent outcome measures. Level of evidence: Not applicable

show abstract

Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis

Cited by 4 publications

References 26 publications

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Impact of Ureteral Stent Material on Stent-related Symptoms: A Systematic Review of the Literature

Ureteroscopic treatment of urolithiasis: How do we measure and optimise outcomes?

Contact Info

Product

Resources

About